Pharma Partners


resistanceBio can work with any company developing novel cancer therapies, regardless of cancer type, therapeutic modality, or stage of development.

ResCu can increase the likelihood of approval by up to 15.7x 

The right treatment for the right patient leads to superior outcomes.

Only novel drug programs that we have confidence will achieve superiority are advanced to the clinic.

Missed endpoints account for up to 53% phase to phase transition holds; ResCu can increase the likelihood of positive patient response, enabling a novel therapy to advance to the next stage in clinical development.  Less than a 53% increase in phase to phase transitions with the help of resistance biomarkers can lead to an increased likelihood of approval of up to 25.3% from 1.6% without biomarkers. 

Single Lead Selection and Optimization

When you only have one shot, make it your best.

With a known target and cancer indication selected,  ResCu can help determine the right lead candidate to advance to the clinic with the least resistance potential and best long-term efficacy.

Multiple Lead Selection and Optimization for the same target and indication

When more is better.

Why advance one lead asset against a target when you can advance multiple? Patient subpopulations can be selected for each potential lead by exploiting the lead compounds’ unique off-target effects. This approach can drastically reduce the per drug clinical trial costs as multiple novel compounds can be tested on the same general indication, with the same doctors, at the same trial sites.

Clinical Trial Patient Stratification

Resistance biomarkers for potentially superior outcomes.

ResCu can reveal how cancer may overcome a therapy preclinically. It ensures that the most promising asset advances to the clinic. These therapies generate a set of resistance biomarkers that can be used to find patients with the drug target and susceptibility biomarker who don’t have the resistance biomarkers. These patients are predicted to have the best treatment response.

Resistance networks are target networks

Treatment resistance targets become the next frontier in novel therapeutic development.

What causes cancer is not what causes cancer treatment resistance. Therapies with high target specificity generate resistance networks. Each resistance network is filled with novel resistance targets and networks unique to a starting therapy. When treated in combination with a resistance-targeted therapy, the starting therapy has substantially improved the long-term efficacy.

Join the future of cancer therapy

ReSTs are target, indication, and treatment modality agnostic.

Partner with resistanceBio to identify novel therapies, enhance approved therapies, improve patient outcomes, and improve portfolio performance by advancing the best treatments in the right patients. 

It’s a new era of first-in-class oncology therapies that target the cause of patient relapse and death;  treatment-resistant cancer.

ReST’s are predicated on drugging new resistance target networks that kill cancer and suppress its ability to become resistant to therapy.